We will bring you a monthly newsletter to update events and news interested to our members. We encourage you to send news to us at news@ sabpa.org. Please submit a brief description and sources, references, or links where we could find more information.
This is the first holiday season since SABPA's inauguration six months ago. We warmly wish you a wonderful Holiday Season and a very Happy New Year!
How is SABPA doing? What should we say to people about SABPA at this moment, the first holiday season in its life? Here is a review and outlook from SABPA Chair and President. (http://www.sabpa.org/About/Newsletters/LetterChair.html)
Perlan Therapeutics, Inc. won UCSD CONNECT's 15th annual Most Innovative New Product (MIP) Awards. This award recognizes the important discoveries that are occurring in San Diego's biotech/life sciences community. This year's seven winners were chosen by a distinguished panel of judges from a field of more than 130 companies. Perlan received the Award for ColdSol(TM), a daily nasal spray being developed for the prevention and treatment of the common cold caused by human rhinovirus. Dr. Fang Fang, Vice President and co-founder of Perlan Therapeutics, Inc., also serves as a board member of SABPA.
For more information about MIP award, please visit http://www.connect.org/programs/mip/index.htm
The Third Ray Wu Society (RWS) Meeting will be held from Dec. 27 to Dec. 30, 2002, at the Hilton Hotel in La Jolla, CA. RWS is a non-profit professional organization of life science. Primarily composed of Chinese natives, at home and abroad, the society requires that its members to have achieved a certain level of career establishment, such as principle investigator (PI) or projector leader (PL). The mission of RWS is to promote the advancement of the life sciences by providing Chinese scientists a platform of professional interactions and collaborations with their peers of other nationalities. The society is also devoted to facilitate the development of life sciences within China. Tentative program and schedule is now available. For more information about RWS, please visit http://info.med.yale.edu/genetics/xu/RWS/
Program: http://www.sabpa.org/About/Newsletters/15Dec2002/Meeting_Program_RWS.pdf
Schedule: http://www.sabpa.org/About/Newsletters/15Dec2002/schedule_RWS.pdf
SABPA is proudly sponsoring the San Diego Hi-Tech Delegation to the Convention of Overseas Chinese Scholars (OSC) in Science & Technology at Guangzhou (Dec. 28 - 30, 2002). The delegation is led by Dr. Ming LI. More than 10 SABPA members are among the delegates. For more information about the San Diego Delegation, please visit delegation's discussion group web http://groups.yahoo.com/group/sd_cn_ht_bridge/. For information about the Convention, please visit: http://www.ocs-gz.gov.cn
Minneapolis based SURG II, Inc. has entered into an agreement to merge with privately-held Chiral Quest, LLC. Chiral Quest is a chemistry research and drug development company focused on commercializing proprietary, patented solutions to improve the manufacturing process for the pharmaceutical, biotechnology and fine chemical industries. The merged company, Chiral Quest Inc, will be a public traded independent chiral chemistry development firm and will be made to trade under the OTCBB symbol: CQST. The company was founded in October 2000 by Dr. Xumu Zhang, Associate Professor of Chemistry at Penn State University. Chiral Quest's technology facilitates the construction of chiral molecules eliminating the need for expensive separation of enantiomers. Chiral Quest is considered an emerging leader in the development of chemical catalysts used in the synthesis of desired isomers of chiral molecules. For more information, please visit http://www.chiralquest.com.
For more Information and registration details, see http://bioscience.ucsd.edu Tel: (858)964-1347 or Email: unexbio@ucsd.edu.
It's been a roller coaster year for pharmaceutical and biotech companies with mergers, buyouts, shut downs, downsizing and cutbacks. If you like to hire people, or know a job opening, please email us at news@sabpa.org so that we could post them to our members. Here are a few recent opportunities.
A San Francisco Bay Area biotechnology company is hiring three Computational Chemists. This company of about 600 employees recently entered into a collaboration with a "Big Pharma" company that will result in their receiving milestone payments of $220 million to $350 million payments that could double if the two companies decide to expand the joint effort. They also have a number of other collaborations and joint ventures with other Big Pharma companies assuring their own stability for some time. For more information please visit: http://www.sabpa.org/Resources/resourcesJobsSanDiegoCA.html
This position is supported by an NIH funded project involving prediction and analysis of drug resistance in HIV mutants. The goal is to develop bioinformatic tools for assessing the efficacy of multi-drug therapies on different mutants of the HIV protease. We seek individuals with a knowledge of enzyme kinetics, strong analytic skills and some experience in algorithm development. We are willing to consider people from a variety of disciplinary backgrounds. For more description of the positions, please visit http://www.sabpa.org/Resources/resourcesJobsSanDiegoCA.html
SABPA is supported by the following sponsors:
